802 articles
BioAge's oral drug BGE-102 cut a key cardiovascular risk biomarker by up to 86% in obese patients, rivaling higher doses at just 60mg daily.
A small RCT found weekly rapamycin reduced functional fitness gains from exercise in adults aged 65–85, raising questions for longevity stackers.
A new analysis links masitinib to a 42% five-year ALS survival rate versus a 23.5% historical benchmark, with median survival nearly tripling.
ACD856 crosses the blood-brain barrier and boosts cognition-linked pathways. Phase Ib is complete, with Phase II for Alzheimer's on the horizon.
Researchers find bone-remodeling drugs reduce aneurysm growth in mice, linking aging blood cell mutations to vascular breakdown.
Hone Health integrates BodySpec DEXA scans into its longevity platform, linking body composition data with hormone and metabolic markers for smarter care.
A five-year NIH grant funds AI analysis of 1,800+ Alzheimer's genes to find drug targets earlier in the disease process.
GSK acquires 35Pharma for $950M, gaining a drug that may treat lung disease while also improving insulin sensitivity and preserving muscle.
Cutting off biotin halts cancer cell growth by disabling a key enzyme, revealing a promising new therapeutic target.
A large 10-year study finds GLP-1 users develop cognitive impairment more often — but mainly because they live longer to face it.
Zoldonrasib targets a previously undruggable KRAS mutation, showing 52% response rate and 11-month progression-free survival in NSCLC.
A large 40-year study finds midlife migraine sufferers face a modest but significant increase in long-term dementia risk.
